Truist cuts Sangamo stock target to $5, maintains Buy rating
Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...
Truist Financial Keeps Their Buy Rating on Sangamo Biosciences (SGMO)
Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...
Sangamo Biosciences Holds Steady Amid Partnership Prospects and Program Uncertainties
Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...
Morningstar17d
Sangamo Therapeutics Inc SGMO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing21d
H.C. Wainwright defends Sangamo shares after sell-off, reiterates Buy on pipeline confidence
On Thursday, H.C. Wainwright reaffirmed a positive stance on Sangamo BioSciences (NASDAQ:SGMO), maintaining a Buy rating and a $10.00 price target. Currently trading at $1.02 with a market ...
Business Wire22d
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics ...
Business Wire22d
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of investors ...
Contract Pharma22d
Sangamo Therapeutics to Regain Rights to Gene Therapy Program from Pfizer
Sangamo Therapeutics, Inc., a genomic medicine company, will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy candidate for the treatment ...